Disc Medicine’s Phase 3 data revives rejected rare‑disease drug as China tightens biotech ownership rules

Disc Medicine announced that its Phase 3 trial of a previously rejected rare‑disease therapy showed positive results, effectively rescuing the program and positioning it for another submission to the FDA.

The data sweep covered multiple endpoints and demonstrated meaningful clinical benefit, which the company says will support a renewed filing later this year.

Meanwhile, China introduced new restrictions on biotechnology ownership transfers, covering areas such as cell and gene therapy, though licensing agreements remain exempt, allowing continued cross‑border collaborations.

Analysts note that Chinese biotech firms have been less active in M&A, with the majority of deals this year originating from U.S. companies, while Chinese entities continue to dominate licensing activity.